WealthTrust Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

WealthTrust Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,043	Closed	-$1.14M	–	80
2025 Q3	$1.14M	Sell	21,043 -881	-4%	-$50.4K	0.79%	28
2025 Q2	$1.21M	Buy	21,924 +11,092	+102%	+$653K	0.9%	28
2025 Q1	$766K	Buy	+10,832	New	+$729K	0.57%	40

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

WealthTrust Asset Management's BMRN Position: Q4 2025 in Review

WealthTrust Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 21,043 shares — an estimated $1.14M sold.

WealthTrust Asset Management first reported a position in BMRN in Q1 2025 and held it in 3 quarters. The position peaked at $1.21M in Q2 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

WealthTrust Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
WealthTrust Asset Management sold 21,043 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.14M.
WealthTrust Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 3 quarters.
WealthTrust Asset Management's BioMarin Pharmaceuticals position peaked at $1.21M in Q2 2025.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on WealthTrust Asset Management's 13F filing for Q4 2025, filed 4 Feb 2026.